ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT (6:45pm ET) on January 10, 2023.
Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 4:05pm PT (7:05pm ET).
A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005216/en/
INVESTOR RELATIONS
ImmunoGen
Anabel Chan
781-895-0600
[email protected]
MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]
OR
FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evergy Schedules Conference Call to Discuss 1st Quarter Results
- BioMedNewsBreaks — Astiva Health Is Redefining Senior Healthcare
- Comfort Systems USA Announces First Quarter 2024 Conference Call and Webcast
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!